Document is current
Any future updates will be listed below
-
Authors
Rubinski, Anna
Franzmeier, Nicolai
Dewenter, Anna
Luan, Ying
Smith, Ruben
Strandberg, Olof
Ossenkoppele, Rik
Dichgans, Martin
Hansson, Oskar
Ewers, Michael
,
-
Funding
Funding for this research was provided by:
German Center for Neurodegenerative Diseases
Deutsche Forschungsgemeinschaft (INST 409/193-1 FUGG)
Universitätsklinik München
- License Information
-
More Information
Article History
Received: 11 May 2022
Accepted: 28 August 2022
First Online: 24 September 2022
Declarations
:
: For ADNI, ethical approval was obtained by the ADNI investigators; all study participants provided written informed consent.For BioFINDER-1, ethical approval was given by the ethics committee of Lund University, Sweden. Imaging procedures were approved by the Swedish Medical Product Agency and the Radiation Safety Committee at Skåne University Hospital, Sweden.
: Not applicable.
: M.E and N.F. receive research funding from Eli Lilly; M.E. serves as a consultant for Eli Lilly. The other authors declare that they have no competing interests.
